Serum hepcidin as a biomarker of treatment response in Gaucher disease. [PDF]
Koppe T +5 more
europepmc +1 more source
Gaucher disease, state of the art and perspectives. [PDF]
Camou F, Berger MG.
europepmc +1 more source
Crossing the barrier: nanomedicine as a frontier therapy for neuropathic Gaucher disease type 3. [PDF]
Saif M +4 more
europepmc +1 more source
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation. [PDF]
Beydon M +31 more
europepmc +1 more source
Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis. [PDF]
Liu Y +6 more
europepmc +1 more source
Microbiome-gut-heart axis in cardiac complications of Gaucher disease type 3. [PDF]
Abedin ZU, Iqbal MU, Shahriar Z.
europepmc +1 more source
Precision genomic profiling in Gaucher disease: insights from atypical presentations. [PDF]
Saith A +9 more
europepmc +1 more source
Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease. [PDF]
Zou J +5 more
europepmc +1 more source
Unexpected Gaucher disease in a case of steroid-resistant nephrotic syndrome. [PDF]
Gehad MH +4 more
europepmc +1 more source

